The preparation is intended for intra-articular injection for the symptomatic treatment of mild to moderate osteoarthritis and for the treatment of pain after arthroscopic procedures. The preparation contains hyaluronic acid of non-animal origin, produced by biosynthesis, which has been purified and stabilized. Hyaluronic acid injections into the joints restore the viscosity and elasticity of the synovial fluid, so they can reduce pain and increase joint mobility.
Purpose: symptomatic treatment associated with the treatment of mild to moderate pain resulting from osteoarthritis of the ankles, elbows, wrists and interphalangeal fingers and toes. The preparation is also indicated for the treatment of pain caused by arthroscopic procedures in the presence of osteoarthritis within three months after surgery.
Usage: the preparation in a single-dose package – one injection. It can be injected only once during the entire treatment cycle. The recommended dose for the knee, hip and shoulder joint is 3ml. For medium-sized joints (e.g. elbow, ankle) a dose of 1-2ml is recommended, and for small joints (e.g. thumb joint) about 1ml.
Ingredients: 1ml of the preparation contains: stabilized hyaluronic acid 20mg, physiological saline solution pH 7.
Contraindications: The preparation should not be injected if the joint is infected or seriously inflamed. It should not be injected if there is an active disease or infection at the injection site or nearby. It should not be used in patients who are hypersensitive to preparations containing hyaluronic acid. Local anesthetics should not be used in patients with known allergy or hypersensitivity to these agents. If the patient has been diagnosed as having an allergy or hypersensitivity to the contrast agent, do not administer the preparation under the fluoroscope, if the use of such contrast agent is required. The preparation should be used with caution in patients with existing chondrocalcinosis, as the injection may lead to an acute attack of the disease.
The preparation should be injected by an authorized doctor.
The preparation should be injected strictly using aseptic technique.
The preparation has not been tested in pregnant women, breast-feeding women and children.
The preparation should only be injected into the joint cavity.
The preparation should not be injected intravenously and extra-articularly, into the synovium and into the joint capsule.
The preparation cannot be sterilized again as it may decompose.
The preparation should be used with increased caution in patients with stagnant leg of venous or lymphatic origin.
A separate syringe with the preparation should be used for each joint being treated.
Due to the invasive nature of intra-articular injection, there is a small risk of infection.
4721 Emperor Boulevard Suite 100
Durham, NC 27703 USA